PortfoliosLab logo
APLS vs. LNTH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between APLS and LNTH is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

APLS vs. LNTH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apellis Pharmaceuticals, Inc. (APLS) and Lantheus Holdings, Inc. (LNTH). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

APLS:

-1.09

LNTH:

-0.09

Sortino Ratio

APLS:

-1.75

LNTH:

0.38

Omega Ratio

APLS:

0.79

LNTH:

1.06

Calmar Ratio

APLS:

-0.71

LNTH:

-0.12

Martin Ratio

APLS:

-1.72

LNTH:

-0.23

Ulcer Index

APLS:

33.78%

LNTH:

21.60%

Daily Std Dev

APLS:

53.78%

LNTH:

65.40%

Max Drawdown

APLS:

-82.47%

LNTH:

-78.62%

Current Drawdown

APLS:

-81.86%

LNTH:

-38.88%

Fundamentals

Market Cap

APLS:

$2.19B

LNTH:

$5.22B

EPS

APLS:

-$1.75

LNTH:

$3.51

PS Ratio

APLS:

2.82

LNTH:

3.40

PB Ratio

APLS:

13.32

LNTH:

4.49

Total Revenue (TTM)

APLS:

$775.84M

LNTH:

$1.54B

Gross Profit (TTM)

APLS:

$643.52M

LNTH:

$984.15M

EBITDA (TTM)

APLS:

-$176.07M

LNTH:

$438.66M

Returns By Period

In the year-to-date period, APLS achieves a -46.94% return, which is significantly lower than LNTH's -15.54% return.


APLS

YTD

-46.94%

1M

-11.87%

6M

-50.10%

1Y

-58.45%

3Y*

-25.80%

5Y*

-12.86%

10Y*

N/A

LNTH

YTD

-15.54%

1M

-27.58%

6M

-15.36%

1Y

-6.16%

3Y*

3.31%

5Y*

40.64%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Apellis Pharmaceuticals, Inc.

Lantheus Holdings, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

APLS vs. LNTH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APLS
The Risk-Adjusted Performance Rank of APLS is 44
Overall Rank
The Sharpe Ratio Rank of APLS is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of APLS is 33
Sortino Ratio Rank
The Omega Ratio Rank of APLS is 55
Omega Ratio Rank
The Calmar Ratio Rank of APLS is 88
Calmar Ratio Rank
The Martin Ratio Rank of APLS is 22
Martin Ratio Rank

LNTH
The Risk-Adjusted Performance Rank of LNTH is 4646
Overall Rank
The Sharpe Ratio Rank of LNTH is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of LNTH is 4747
Sortino Ratio Rank
The Omega Ratio Rank of LNTH is 4848
Omega Ratio Rank
The Calmar Ratio Rank of LNTH is 4343
Calmar Ratio Rank
The Martin Ratio Rank of LNTH is 4646
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

APLS vs. LNTH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Lantheus Holdings, Inc. (LNTH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current APLS Sharpe Ratio is -1.09, which is lower than the LNTH Sharpe Ratio of -0.09. The chart below compares the historical Sharpe Ratios of APLS and LNTH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

APLS vs. LNTH - Dividend Comparison

Neither APLS nor LNTH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

APLS vs. LNTH - Drawdown Comparison

The maximum APLS drawdown since its inception was -82.47%, roughly equal to the maximum LNTH drawdown of -78.62%. Use the drawdown chart below to compare losses from any high point for APLS and LNTH.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

APLS vs. LNTH - Volatility Comparison

The current volatility for Apellis Pharmaceuticals, Inc. (APLS) is 15.97%, while Lantheus Holdings, Inc. (LNTH) has a volatility of 27.52%. This indicates that APLS experiences smaller price fluctuations and is considered to be less risky than LNTH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

APLS vs. LNTH - Financials Comparison

This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Lantheus Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M20212022202320242025
166.80M
372.76M
(APLS) Total Revenue
(LNTH) Total Revenue
Values in USD except per share items

APLS vs. LNTH - Profitability Comparison

The chart below illustrates the profitability comparison between Apellis Pharmaceuticals, Inc. and Lantheus Holdings, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20212022202320242025
79.4%
63.8%
(APLS) Gross Margin
(LNTH) Gross Margin
APLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a gross profit of 132.44M and revenue of 166.80M. Therefore, the gross margin over that period was 79.4%.

LNTH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported a gross profit of 237.70M and revenue of 372.76M. Therefore, the gross margin over that period was 63.8%.

APLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported an operating income of -83.33M and revenue of 166.80M, resulting in an operating margin of -50.0%.

LNTH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported an operating income of 102.07M and revenue of 372.76M, resulting in an operating margin of 27.4%.

APLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a net income of -92.23M and revenue of 166.80M, resulting in a net margin of -55.3%.

LNTH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported a net income of 72.95M and revenue of 372.76M, resulting in a net margin of 19.6%.